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1. Summary
The complexityof signalling pathwayswas boosted at the origin of the vertebrates,
when two rounds of whole genome duplication (2R-WGD) occurred. Those genes
and proteins that have survived from the 2R-WGD—termed 2R-ohnologues—
belong to families of two to four members, and are enriched in signalling com-
ponents relevant to cancer. Here, we find that while only approximately 30% of
human transcript-coding genes are 2R-ohnologues, they carry 42–60% of the
gene mutations in 30 different cancer types. Across a subset of cancer datasets,
including melanoma, breast, lung adenocarcinoma, liver and medulloblastoma,
we identified 673 2R-ohnologue families in which one gene carries mutations at
multiple positions, while sister genes in the same family are relatively mutation
free. Strikingly, in 315 of the 322 2R-ohnologue families displaying such a skew
in multiple cancers, the same gene carries the heaviest mutation load in each
cancer, and usually the second-ranked gene is also the same in each cancer. Our
findings inspire the hypothesis that in certain cancers, heterogeneous combi-
nations of genetic changes impair parts of the 2R-WGD signalling networks and
force information flow through a limited set of oncogenic pathways in which
specific non-mutated 2R-ohnologues serve as effectors. The non-mutated
2R-ohnologues are therefore potential therapeutic targets. These include proteins
linked to growth factor signalling, neurotransmission and ion channels.
2. Introduction
Over 500million years ago, the vertebrates emerged from their invertebrate ances-
tor via an evolutionary leap involving two rounds of whole genome duplication
(2R-WGD) [1–5]. Most of the resulting quadruplicated genes and proteins,
termed 2R-ohnologues, were lost. However, the few thousand families of two
to four 2R-ohnologues that still survive in modern humans are remarkably
enriched in signalling molecules. These include families of growth factors, recep-
tors, protein kinases, GTPases and their regulators, ion channels, transcription
factors, developmental regulators and proteins that interact transiently with
multi-protein complexes, andmany of these are also 14-3-3-binding phosphopro-
teins [6,7]. By contrast, core components of stablemulti-protein complexes such as
RNA polymerases and the proteasome, and genes that were duplicated by small-
scale genomic events after the 2R-WGD, tend not to be 2R-ohnologues [8,9]. These
& 2014 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
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findings indicate that the 2R-WGD provided a selective boost
to regulatory systems, which enabled vertebrate life to evolve.
However, there appears to be a downside to the vertebrate
style of signalling complexity: several studies have highlighted
that 2R-ohnologue dysregulations are highly linked to neurode-
velopmental and metabolic disorders, and to cancers [7,10,11].
Most cancers rely on a restricted number of ‘driver’
mutations, which confer cells with selective advantages that pro-
mote cancer initiation, progression and metastasis. Some driver
mutations inactivate tumour suppressors suchasp53,whichnor-
mally induces growth arrest or apoptosis in stressed cells. Other
drivers involve specific gene fusions, or point mutations such as
B-RafV600E, K-RasG12D and N-RasQ61R, which activate oncogenic
signallingpathways [12–14]. At the biochemical level, oncogenic
signalling stimulates multiple intracellular changes that together
promote the cancer phenotype. Interestingly,many tumour sup-
pressors and oncogenic drivers, including p53, B-Raf and Ras
proteins, belong to 2R-ohnologue families [11].
In addition to drivers, cancers can accumulate heavy loads of
somatic mutations [15]. Most are considered to be ‘passengers’
that do not contribute to cancer progression [16]. However, we
reasoned that there must be constraints on which mutations
are compatible with any given oncogenic driver. If too many
of the proteins that enact the downstream functions of an onco-
genic driver were to suffer deleterious passenger mutations, the
driverwould lose its efficacy. Then, the cancer cell lineagewould
die out or become quiescent unless it acquired a different driver
mutation that operates via a different mechanism, which might
help explain cancer heterogeneity [17–19].
This study investigates how somatic mutations in cancers
are distributed within families of 2R-ohnologue signalling
genes. A general characteristic of 2R-ohnologues is that the
domain architectures of the encoded proteins are conserved
across each family. Therefore, the broad expectation is formem-
bers of a given family to share a high degree of overlap in their
core functions. On the other hand, owing to localized sequence
changes, family members may differ in their expression pat-
terns, post-translational modifications, regulation by protein
kinases, kinetic rates, binding affinities and substrate selectiv-
ities [8,20–23]. We therefore conceptualize each 2R-ohnologue
protein family as a multiple-input multiple-output (MIMO)
system that integrates different input signals to produce a
combined functional output [7,24]. The phenotype of a cell
will depend on which combinations of 2R-ohnologues from
each family are expressed and engaged by the signalling
pathways that operate in any physiological context [7,24].
Stemming from theMIMO signal-multiplexing concept, we
hypothesized that 2R-ohnologues that are positive effectors
of an active oncogenic driver should be kept free of loss-
of-function mutations in a cancer. By contrast, mutations may
accumulate in sister 2R-ohnologues that are components of sig-
nalling networks that are irrelevant or inhibitory to the cancer.
Finding the putative non-mutated 2R-ohnologues would need
cumulative data from multiple samples, because each cancer
cell lineage might have only a few of the allowed mutations
spread among many 2R-ohnologue families. The recent avail-
ability of large datasets of mutations in a variety of cancer
types [15,25] therefore provided the first opportunity to explore
this hypothesis. We reveal striking hierarchical patterns in
the distributions of mutations within 2R-ohnologue families
in cancers. Our findings support the concept of selected 2R-
ohnologues being maintained free of mutations as ‘effectors’
in certain cancers.
3. Results
3.1. 2R-ohnologues carry a higher relative mutation
load than non-ohnologues in every cancer
type examined
Alexandrov et al. [15] validated almost 5 million somatic
mutations identified in the genome sequences of 7042 samples
from 30 different cancer types, but not in matched DNA from
normal cells. We used the Alexandrov data to examine the dis-
tribution of mutations in 2R-ohnologue versus non-ohnologue
genes (electronic supplementary material, table S1). A striking
imbalance was revealed (figure 1). Although 2R-ohnologues
comprise only approximately 30% of protein-coding genes in
the human genome (figure 1a), they carry a higher proportion
of the somatic mutations in transcript-coding genes in every
cancer examined (figure 1b; statistics in the electronic
supplementary material, figure S1). The proportions range
from 42% of gene mutations located in 2R-ohnologues in
kidney clear cell carcinoma to 60% in liver cancer and in
B-cell lymphoma. The greater prevalence of mutations
among 2R-ohnologues is not due to differences in gene sizes:
2R-ohnologue genes average 2400 nucleotides in length and
non-ohnologues 2200 nucleotides (electronic supplementary
material, figure S2).
3.2. Identification of 2R-ohnologue families in which
one gene carries most of the mutations
We next investigated how the somatic mutations are distribu-
ted among members of each 2R-ohnologue family, analysing
each cancer type separately. To this aim, each 2R-ohnologue
gene was given a mutation load (ML) score (electronic sup-
plementary material, table S2). A gene that accumulates most
of the mutations for its 2R-ohnologue family scores close to
1, while genes that are clear of mutations relative to their
sister genes score close to 0. Repeats of mutations at the same
position were scored as a single mutation because we did not
wish to rediscover, nor have the analysis dominated by, recur-
rent driver mutations. Also, we included only families for
which at least one gene carried 10 or more different mutations
in the cancer type. This method therefore captured genes with
broad patterns of mutations at multiple positions.
The ML distributions for the melanoma dataset are
graphed in figure 2a and for other cancers in the electronic sup-
plementary material, data file S1 (with statistical note in
legend). In melanoma and other tumour types, there were
2R-ohnologue families in which the MLs were evenly distribu-
ted among family members, such as the HECW family of two
E3 ubiquitin ligases (figure 2b). However, in most cancers,
including melanoma, there were also 2R-ohnologue families
with a ‘skewed ML’, meaning that one gene carried most of
the ML. For example, in the melanoma dataset PAK7 carries
95 of the 114 mutated sites in the family of three type II PAK
protein kinases (figure 2b).
By contrast, there were no 2R-ohnologue families with
skewed MLs in cervical, thyroid, myeloma and kidney papil-
lary cancers (electronic supplementary material, tables S1
and S2). This was likely to be due to insufficient data for
these cancer types; there were 10 or more mutations in only
23 2R-ohnologue genes in the cervical cancer samples, seven
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in thyroid, one in myeloma and nine in kidney papillary
cancer samples. This may also be indicative of particular
tumourigenesis mechanisms acting in these cancers.
3.3. In 315 2R-ohnologue families, the same
gene carries the highest mutation load in
multiple cancers
A total of 673 2R-ohnologue families displayed highly skewed
MLs in one or more cancers (electronic supplementary
material, table S3). This dataset was visualized in a VisANT
network graph inwhich each cancer type is assigned a hexago-
nal blue node, connected to circular nodes (green, red or
orange) that each represent a 2R-ohnologue family with a
skewed ML in that cancer (figure 3). The ‘elegant relaxing’
VisANT rule was applied [27], which means that 2R-
ohnologue families with a skewed ML in only one cancer fan
to the outside of the graph, while those with a skewed ML in
multiple cancers are pulled towards the centre (figure 3). The
layout of the graph therefore reflects patterns in the data.
Cancers around the top and sides of the graph, namelymel-
anoma, breast, lung adenocarcinoma, liver, pancreatic, B-cell
lymphoma and chronic lymphocytic leukaemia (CLL), are
characterized by relatively high numbers ofML-skewed families
(figure 3). Each of these cancers has 2R-ohnologue families for
which ML skews were identified only in the individual cancer,
which may be ‘signatures’ reflecting the tissues of origin of
these cancers.However, these cancers are also highly interlinked
by the many other ML-skewed 2R-ohnologue families that they
have in common. Paediatric medulloblastoma is also highly
interlinked, being central on the graph because it shares 120
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Figure 1. Distributions of cancer mutations between 2R-ohnologue and non-ohnologue transcript-coding genes in 30 different cancers. (a) The bar shows the
percentage of 2R-ohnologue and non-ohnologue transcript-coding genes in the Ensembl 72 dataset, based on the provisional 2R-ohnologue list compiled by
Makino & McLysaght [10]. Note that assignment of which human genes are 2R-ohnologues is still undergoing revision. (b) For each cancer type analysed
[15], the graph on the left side reports the percentage of mutations that map on 2R-ohnologue and non-ohnologue genes. The right side reports the log10
value of the total number of mutations identified in each cancer type in this dataset.
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ML-skewed families with other cancers, while only 20 ML-
skewed families are unique to medulloblastoma (figure 3;
electronic supplementary material, table S3).
Overall, 322 2R-ohnologue families displayed a ML skew
in two or more cancers (electronic supplementary material,
table S3). Remarkably, in 315 of these 322 families, the
same gene carried the highest ML in each of the linked
cancer types (figure 3; electronic supplementary material,
table S3 with statistical note in legend, and data file S2). Fur-
thermore, in most of these 322 families, the same gene carried
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Figure 2. MLs of 2R-ohnologue genes in melanoma. (a) For the melanoma dataset [15], the figure plots the ML distribution for 2R-ohnologues within families of 2,
3 and 4 members. Only families in which at least one gene carries carried 10 or more different mutations are included. The ML is computed by summing the total
number of mutations identified for a gene divided by the total number of mutations in all members of the same 2R-ohnologue family. The y-axes give the number
of genes, with the ML scores indicated on the x-axes. Each histogram set indicates the medians (red lines), interquartile ranges (rectangular boxes) and outliers
(green diamonds) for the ML distributions. Note that for families of 2 members, the median will always be 0.5 by construction, regardless of the ML distribution
profile. Data file S1 in the electronic supplementary material presents the corresponding histograms for 30 cancer types, and its legend contains a discussion note
about statistics. (b) The distribution of mutations in melanoma is given for the HECW E3 ubiquitin ligase family (as an example of even ML distribution) and the
type II PAK family (an example with a skewed ML where the PAK7 gene accumulates most of the family mutations). Illustrations were created with DOMAIN GRAPH,
v. 1.0.5 [26]. CDS is coding sequence, UTR refers to 30 and 50 UTRs, and mutations are indicated by vertical black lines. Data file S2 in the electronic supplementary
material gives similar diagrams for the distributions of mutations in other 2R-ohnologue families in melanoma.
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the second highest ML for each family in each of the linked
cancer types (table 1; electronic supplementary material,
table S3, and statistical note in legend). For example, in the
cumulative data for nine cancer types, the protein receptor
tyrosine phosphatase PTPRD has many more mutated sites
than PTPRS, while PTPRF is rarely mutated; in seven cancers,
the Discs large homologue DLG2 is by far the most often
mutated, DLG1 second, and DLG3 and DLG4 rarely mutated;
the EGF receptor family member ERBB4 carries far more
mutations than EGFR, while ERBB2 (HER2) and ERBB3
have relatively few nucleotides mutated in seven cancers
(table 1; electronic supplementary material, table S3). Thus,
the relative MLs in such 2R-ohnologue families are under
selection pressures that act in a quantitative manner.
We checked whether any of the genes with low ML scores
in these 322 families had recurrent mutations in the same pos-
ition, indicative of potential drivers. However, there were few
repeated mutations in these low-ML genes.
3.4. A distinct group of cancers in which p53 is
the most mutated member of the p53/63/73
family has low connectivity to other mutation
load-skewed families
The ML skew characteristics of cancers in different regions of
figure 3 are summarized in table 2. Interestingly, a distinct
cluster of cancers at the bottom of the graph is characterized
by a high ML skew in the p53/63/73 family (red node on
figure 3). Green nodes are relatively sparse in this region of
the graph, meaning that these cancers have ML skews in rela-
tively few other 2R-ohnologue families. Furthermore, the ML-
skewed families associatedwith this cancer cluster are generally
not shared by cancers in the upper region of the graph.
The p53 gene has a higher ML than p63 and p73 in most
of the cancers in this lower cluster, namely acute myeloid leu-
kaemia (AML), acute lymphoblastic leukaemia (ALL),
bladder, colorectal, esophageal, glioblastoma, low-grade
glioma, head-and-neck, chromophobe renal cell carcinoma,
small cell lung carcinoma and lung squamous cancers
(electronic supplementary material, figure S3; figure 3).
However, the p53/63/73 family was one of only seven 2R-
ohnologue families whose ML skew switched according to
cancer type, and p63 has a far higher ML than p53 and p73
in medulloblastoma (electronic supplementary material,
table S3 and figure S3). Medulloblastoma has a low incidence
of p53 mutations associated with poor prognosis in subtypes
with activated Wnt signalling and polyploid cases with acti-
vated hedgehog signalling, but p53 mutations are generally
not in Group 3 and 4 subtypes [28–30]. However, p63
mutations were found in every medulloblastoma subtype
(electronic supplementary material, table S4).
Cancers in the upper region of figure 3, such as mela-
noma, breast and liver cancer, are not linked to the p53/
63/73 family node because, while these cancers can carry
Figure 3. VisANT map of 2R-ohnologue families that display skewed MLs in different cancer types; graph created using VisANT (visant.bu.edu [27]) from the data in the
electronic supplementary material, table S3. Each cancer was assigned a node in blue and lines connect these cancers to the 2R-ohnologue families (in green, red or
orange) that display a skewed ML in that cancer. For a line to join a cancer and a 2R-ohnologue family, at least one gene in the family had to carry at least 10 different
mutations in that cancer. Also, we plotted only those families with ML skew above the thresholds of at least 0.9 for families containing two genes (that is one gene carried
more than or equal to 90% of the mutated positions for its family), at least 0.8 for families with three genes and at least 0.7 for families of four genes. The red node
labelled ‘P53-F’ is the p53/p63/p73 family, and the orange node marked ‘FOG-F’ represents FOG1/FOG2.
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Table 1. Rank orders of ML scores within ML-skewed families. Electronic supplementary material, table S3, and ﬁgure 3 contain data for all the 2R-ohnologue
families that have extreme ML skews. This table shows only those families of three and four members with high ML skews in at least four cancers. The table
shows which 2R-ohnologues carry the highest number and second highest number of different mutations for its family. The last column indicates how many
cancers have that same rank order of MLs for each family. The ML scores for the 2R-ohnologue families of two members can be viewed in the electronic
supplementary material, table S3. The family identiﬁer is an arbitrary number assigned to each 2R-ohnologue family in [7].
2R-ohnologue family identiﬁer number
and family description
most mutated
member of the
2R-ohnologue
family
second most
mutated
family
member
least mutated
family
member(s)
no. cancers where the
proteins indicated to the
left are ranked ﬁrst and
second most mutated in
the family
60 P53 tumour suppressor family P53 P63 P73 13 of 14
177 cyclic nucleotide-gated ion
channels
HCN1 HCN4 HCN2, HCN3 10 of 10
309 receptor tyr phosphatases PTPRD PTPRS PTPRF nine of nine
904 low-density lipoprotein
receptors
LRP1B LRP2 LRP1 nine of nine
724 N-acetylglucosaminyltransferases MGT4C MGT4A MGT4B eight of eight
1621 bHLH transcription factors NPAS3 SIM1 NPAS1, SIM2 seven of eight
66 Ca2þ-binding cadherin-like CSTN2 CSTN1 CSTN3 seven of seven
170 very long chain acyl-CoA
synthetases
S27A6 S27A2, S27A3 seven of seven for ﬁrst;
others equal
219 phosphatidylserine receptors BAI3 BAI1 BAI2 seven of seven
289 RNA-binding proteins RALYL RALY HNRPC, HNRCL seven of seven
689 Kv channel-interacting proteins KCIP4 KCIP1 CSEN, KCIP2 seven of seven
785 EGF receptor family ERBB4 EGFR ERBB2, ERBB3 seven of seven
1117 Discs large homologues DLG2 DLG1 DLG3, DLG4 seven of seven
1547 transmembrane proteins TM14B TM14C TM14A seven of seven for ﬁrst;
ﬁve of seven for second
1706 autism susceptibility AUTS2 FBSL FBRS six of seven
1727 engulfment and cell motility
proteins
ELMO1 ELMO2 ELMO3 seven of seven for ﬁrst;
six of seven for second
61 Kv channel subunits KCAB1 KCAB2 KCAB3 six of six
89 synaptophysin-like proteins SYNPR SYPL1, SYPL2, SYPH six of six for ﬁrst, others
equal
157 leucine-rich repeat proteins LRRC7 LAP2 SCRIB, LRRC1 six of six for ﬁrst, ﬁve of six
for second
246 choline transporter-like CTL5 CTL2 CTL4 six of six for ﬁrst, ﬁve of six
for second
277 Kv channel subunits KCND2 KCND3 KCND1 six of six
482 liprin family LIPA2 LIPA1 LIPA3, LIPA4 six of six
725 guanine exchange factors for
ARF GTPases
PSD3 PSD2 PSD1, PSD4 six of six for ﬁrst, three of
six for second
948 protein kinase D family KPCD1 KPCD3 KPCD2 six of six
1327 Dickkopf-related, Wnt
antagonists
DKK2 DKK4, DKK1 six of six for ﬁrst, others
equal
2105 C2-containing calcium sensors RP3A DOC2A DOC2B six of six
2215 type II cdc42-interacting protein
kinases
PAK7 PAK4, PAK6 six of six for ﬁrst, others
equal
(Continued.)
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Table 1. (Continued.)
2R-ohnologue family identiﬁer number
and family description
most mutated
member of the
2R-ohnologue
family
second most
mutated
family
member
least mutated
family
member(s)
no. cancers where the
proteins indicated to the
left are ranked ﬁrst and
second most mutated in
the family
2275 RNA-binding splicing regulators RFOX1 RFOX3 RFOX2 six of six for ﬁrst, ﬁve of six
for second
28 zinc transporters ZNT8 ZNT4 ZNT2, ZNT3 ﬁve of ﬁve for ﬁrst, four of
ﬁve for second
47 histone lysine
N-methyltransferases
SMYD3 SMYD1 SMYD2 ﬁve of ﬁve for ﬁrst, three of
ﬁve for second
139 PI 3-kinase regulatory subunits P85A P85B P55G ﬁve of ﬁve for ﬁrst, four of
ﬁve for second
287 muscarinic acetylcholine
receptors
ACM2 ACM3 ACM1, ACM5 four of ﬁve for ﬁrst, four of
ﬁve for second
479 a synaptotagmin family SYT1 SYT2 SYT5 ﬁve of ﬁve
515 hypoxia-inducible prolyl
hydroxylases
EGLN3 EGLN1 EGLN2 ﬁve of ﬁve
525 protein kinase B family AKT3 AKT2 AKT1 ﬁve of ﬁve for ﬁrst, four of
ﬁve for second
649 single-stranded DNA/RNA
interacting
RBMS3 RBMS1 RBMS2 ﬁve of ﬁve
806 type II histone deacetylases HDAC9 HDAC4 HDAC5, HDAC7 ﬁve of ﬁve
872 integrin alpha family ITA8 ITAV ITA2B, ITA5 ﬁve of ﬁve for ﬁrst, four of
ﬁve for second
882 accessory to TGFbeta assembly LTBP1 LTBP2 LTBP3, LTBP4 ﬁve of ﬁve
941 serotonin receptors 5HT2C 5HT2A 5HT2B ﬁve of ﬁve
1085 diacylglycerol kinases DGKB DGKG DGKA ﬁve of ﬁve
1443 zinc-ﬁnger DNA-binding
proteins
ZMAT4 ZMAT1 ZN346 ﬁve of ﬁve for ﬁrst, three of
ﬁve for second
1996 localization of receptors
and ion channels
LIN7A LIN7C LIN7B four of four for ﬁrst, three of
four for second
106 voltage-gated calcium channel
subunits
CAC1C CAC1D CAC1S, CAC1F four of four
140 Rab3 GTPase in exocytotic
vesicle fusion
RAB3C RAB3B RAB3D, RAB3A four of four for ﬁrst, three of
four for second
193 transcription factors RUNX1 RUNX2 RUNX3 four of four
196 regulator in Ras signalling
pathway
CNKR2 CNKR3 CNKR1 four of four for ﬁrst, three of
four for second
254 deubiquitylating enzymes OTU7A OTU7B TNAP3 four of four
386 dynamin vesicle trafﬁcking
proteins
DYN3 DYN1, DYN2 four of four for ﬁrst, others
equal
541 RNA-splicing protein CELF4 CELF5 CELF3, CELF6 four of four for ﬁrst, three of
four for second
632 poly(rC)-binding proteins PCBP3 PCBP2 PCBP1, PCBP4 four of four
915 RNA-binding zinc-ﬁnger
proteins
Z385D Z385B Z385A four of four
(Continued.)
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various mutations in p53 and p63, they do not display
a strong ML skew in this gene family (table 2; electronic
supplementary material, figure S3).
3.5. The p53/63/73 and FOG1/2 mutation
load-skewed families together link to
22 of the 30 cancers examined
The p53/63/73 family has an ML skew in 14 cancer types (red
nodes in figures 3 and 4a). Also linked to many cancers is the
FOG1/2 (Friend of GATA 1/2) family in which FOG2 is
more commonlymutated than FOG1 (orange node on figures 3
and 4a; electronic supplementary material, table S3). Between
them, the p53/63/73 and FOG1/2 ML-skewed families link
to 22 of the 30 cancers examined, with an overlap of only
three cancer types (figure 4a). Other 2R-ohnologue families
displaying high ML skews in 10 or more cancers are those
with the following proteins most mutated: potassium/
sodium hyperpolarization-activated cyclic nucleotide-gated
channel 1 (HCN1), tectorin alpha (TECTA), receptor-type
tyrosine-protein phosphatase delta (PTPRD), low-density
lipoprotein receptor-related protein 1B (LRP1B), MAM
domain-containing glycosylphosphatidylinositol anchor pro-
tein 2 (MDGA2) and protein phosphatase 1 regulatory
subunit 9A (neurabin-1) (electronic supplementary material,
table S3).
3.6. 2R-ohnologue families with skewed mutation loads
in cancer samples that carry activating driver
mutations in B-Raf and N-Ras
We hypothesized that cancers with drivers that activate
different signalling pathways may depend on different sub-
sets of non-mutated 2R-ohnologue effectors. Therefore, from
the 7042 samples in the dataset [15], we selected those with
activating mutations in either B-Raf or N-Ras (electronic sup-
plementary material, table S5). Generally, these two
mutations are mutually exclusive. A subset of skewed-ML
families co-occurred with either B-RafV600E or N-RasQ61K/R
in melanoma (figure 4b). Of these, a smaller subset of families
had ML skews in both the Raf- and Ras-mutated melanoma
samples; these included the type II PAK kinases (PAK7
most mutated) and FOG1/2 family (FOG2 most mutated)
(figure 4b; electronic supplementary material, table S5).
By contrast, in colorectal cancer the p53 family was one of
seven families whose ML skew (p53 most mutated) coincided
with B-RafV600E mutations, while the adenomatous polyposis
coli family (APC more mutated than APC2) had ML skews
in colorectal cancers with either B-RafV600E or N-RasQ61K/R
(figure 4b). Thus, our unbiased analysis rediscovered the
well-known dominance of APC driver mutations in these
tumours, which can also acquire Ras and p53 driver muta-
tions as they progress [31]. We note that as well as the V600E
driver mutation, B-Raf acquired 107 different mutations
in the colorectal cancer samples (electronic supplementary
material, table S3). Finding that many different B-Raf
mutations are allowed to occur in colorectal cancer (as well
as the fact that APC mutation dominates) is consistent
with findings that B-RafV600E inhibitors are generally not
therapeutically useful in this tumour type [31–33].
3.7. The relative mutation load of a 2R-ohnologue
is moderately predictive of its altered mRNA
expression in melanoma
An important question is whether the 2R-ohnologues that are
relatively free of mutations are expressed in the cancers.
While we cannot answer this question for the Alexandrov
et al. [15] dataset, other available data record differences in
mRNA levels between samples ofmalignant cancers compared
with benign or normal controls. We found a moderate, but
statistically significant tendency for 2R-ohnologues with low
ML scores (mutation-free relative to sister 2R-ohnologues) to
have their mRNA levels strongly upregulated in melanoma
in the E-GEOD-3189 dataset [34] (figure 5; electronic sup-
plementary material, figure S4 and table S6). A similar trend
was observed in the E-GEOD-32867 dataset, which reports
gene expression levels in lung adenocarcinoma relative to adja-
cent non-tumour tissue (electronic supplementary material,
figure S5 and table S7). These results indicate the existence of
selection pressures that affect the expression levels of certain
Table 1. (Continued.)
2R-ohnologue family identiﬁer number
and family description
most mutated
member of the
2R-ohnologue
family
second most
mutated
family
member
least mutated
family
member(s)
no. cancers where the
proteins indicated to the
left are ranked ﬁrst and
second most mutated in
the family
1103 cell adhesion molecules CD166 MUC18 BCAM four of four for ﬁrst, two of
four for second
1909 exocytosis, regulated by
diacylglycerol
UN13C UN13B UN13A four of four for ﬁrst, two of
four for second
2301 vesicle regulators alcohol
dehydrogenase family
VAT1L ZADH2 VAT1 four of four
2377 histone demethylases KDM6A UTY KDM6B four of four for ﬁrst, three of
four for second
rsob.royalsocietypublishing.org
Open
Biol.4:140029
8
 on May 19, 2016http://rsob.royalsocietypublishing.org/Downloaded from 
2R-ohnologues in cancer cells. The 2R-ohnologues whose
expression is altered in the cancer have a greater tendency to
be maintained with a low ML.
3.8. 2R-ohnologues with low mutation loads can be
isolated by 14-3-3-affinity capture from lysates
of melanoma cells
Wealsowished to assesswhether 2R-ohnologueswith lowMLs
are expressed as proteins in the relevant cancers. To this end,
we took advantage of the fact that Ras–Raf and certain other
oncogenic signalling pathways stimulate the phosphoryla-
tion of many proteins that consequently dock onto the
phosphoprotein-binding 14-3-3 proteins [35–37]. Moreover,
the 14-3-3-binding phosphoproteome is enriched in
2R-ohnologues [7,38–41].
14-3-3-affinity capture was therefore used to isolate (phos-
pho)proteins from lysates of SKMEL13 melanoma cells that
carry B-RafV600E and also SBCL2 N-RasQ61K melanoma cells
(electronic supplementary material, figure S6, and tables S8
and S9). Of the 1007 proteins that were 14-3-3-affinity captured
and identified in a total of two experiments from both
cell lysates, 68 were previously reported 14-3-3-binding
phosphoproteins (gold standards), and 480 proteins were 2R-
ohnologues. Of these, 62 had ML scores of less than 0.2 in the
melanoma dataset of 2R families in which at least one
member had 10 or more mutations (electronic supplementary
material, table S10). These results indicate that at least some
2R-ohnologues with low ML scores are expressed as proteins
in relevant cancer cells.
Table 2. Characteristics of cancers in different regions of the VisANT graph in ﬁgure 3. In this table, cancers are loosely clustered according to the indicated
characteristics. The data for mutations in p53, p63 and p73 for all cancers (from electronic supplementary material, table S2) are summarized in the electronic
supplementary material, ﬁgure S5. Note that for all cancers with at least 10 mutations in at least one member of the p53/p63/p73 family, p73 always carries
the lowest number of mutations in this dataset (electronic supplementary material, ﬁgure S3).
position on
graph in
ﬁgure 3 cancers in cluster connected to ML-skewed families
above-threshold ML skew within
p53/63/73 family?
top and sides melanoma, B-cell lymphoma, breast,
CLL, liver, lung adenocarcinoma,
pancreatic, stomach, uterus
highly connected. Each cancer has both
unique and shared ML-skewed
families
no: melanoma, liver and B-cell
lymphoma have most mutations in
p63, while the other cancers have
p53 as the most mutated protein,
but these trends are below the
skew thresholds for these cancers
to be linked to the p53/p63/p73
in ﬁgure 3
centre medulloblastoma highly connected, with 120 ML-skewed
families shared with other cancers
and 20 ML-skewed families unique
to medulloblastoma
yes: p63 is the most mutated
member of this family
bottom ALL, AML, bladder, colorectal,
esophageal, glioblastoma, glioma
(low grade), head-and-neck, lung
squamous, ovary, prostate, kidney
chromophobe
relatively few ML-skewed families are
linked to each cancer in this cluster
yes: p53 is the most mutated
member of this family
unconnected cervical, kidney papillary, kidney clear
cell carcinoma, myeloma, thyroid
unconnected to any ML-skewed families no: cancers have fewer than nine
mutations in p53/p63/p73 family
in this dataset
neuroblastoma only one ML-skewed family, namely
ALK/LTK (ALK most mutated,
including well-known mutations)
no: only one p53 mutation and two
p63 mutations in dataset
pilocytic astrocytoma connected to only three ML-skewed
families, two of which are also
highly connected to other cancers
(LRP1B-most mutated, PTPRD-most
mutated), the third being the Raf
family (B-Raf most mutated)
no: only two mutations in the
p53/p63/p73 family in dataset;
one in p63 and one in p73
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Further analysis identified candidate ‘lynchpin’ 14-3-3-
binding phosphosites in 286 of the melanoma 14-3-3-affinity
captured 2R-ohnologues [42]. Lynchpins are 14-3-3-binding
phosphosites whose positions are conserved across mem-
bers of a given 2R-ohnologue family [7]. From the overall
analysis, we assembled a stringent list of 235 known and
candidate 14-3-3 binding partners (electronic supplemen-
tary material, table S10). Interestingly, 143 proteins from
this stringent list could be mapped to the E-GEOD-3189
melanoma transcriptome dataset and were moderately over-
represented among 2R-ohnologues with low ML scores
(figure 5). Specifically, 111 of these 143 (78%) 14-3-3-affinity
captured proteins were among the 66% of this dataset that
had ML scores of less than 0.5 (electronic supplementary
material, table S6). In summary, these pilot experiments
indicate the potential of 14-3-3-affinity capture for isolating
DLG-F
RALY
PICAL-F
HOOK-F
HDAC-F
T151-F
APC-F
TECTA-F
FREM-F
SIAT-F
PAK-F
FOG-F
STB5L-F
GREB1-F
RFOX-F
MDGA-F
RP3-F
NOL4-F
HMGC-F
ARP2-F
ERC2-F
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TM14-F
FA59-F
IQCA1-F
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AAPK-F
KLC-F
PKHH-F
P53-F
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common
COLORECTUM
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PHLB-F
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LUNG_SQUAMOUS
LYMPHOMA_B-CELL
ESOPHAGEAL
PROSTATE
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(a)
Figure 4. Associations between specific cancers and specific mutation-load-skewed 2R-ohnologue families. (a) Data extracted from figure 3, showing the cancers
for which there are ML skews in the p53/p63/p73 and FOG1/FOG2 protein families. (b) A graph showing those 2R-ohnologue families that display a skewed ML
in the cumulative data from those melanoma and colorectal cancer samples that have either a B-RafV600E or N-RasQ61K/R mutation (data in the electronic sup-
plementary material, table S5). ‘Common’ indicates 2R-ohnologue families that have a skewed ML in the data from both the B-RafV600E-mutated and the
N-RasQ61K/R-mutated samples.
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2R-ohnologue proteins to dissect their biochemical regulation
in cancers.
3.9. Overexpression of protein kinase 2R-ohnologues
with low mutation load scores decreased the
sensitivity of B-RafV600E-mutant melanoma cells
to PLX4720
One further observation is consistent with the notion that 2R-
ohnologues with low ML scores are functionally relevant for
cancer: Wood et al. [43] screened for protein kinases whose
overexpression rendered B-RafV600E-melanoma cells resis-
tant to the B-RafV600E inhibitor, PLX4720. We noted that
2R-ohnologue protein kinases with low ML scores in mela-
noma (this study) tended to be better at rendering cells
resistant to PLX4720 [43], compared with their sisters that
have high ML scores (table 3). The trend of ‘highest viability
score ¼ lowest ML score’ was observed even within protein
kinase families that display moderate ML skews in melanoma
(table 3). This finding suggests that the protein kinases with
low ML scores may contribute to melanoma progression by
a mechanism that is linked to B-RafV600E.
4. Discussion
Here, knowledge of the evolutionary history of the human
genome was used to unlock patterns in a heterogeneous data-
set of somatic mutations from many cancers. Our findings
cannot be accommodated within the conventional binary
driver/passenger model [16,32].
In every cancer type examined, somatic mutations are
more prevalent in 2R-ohnologues than in non-ohnologue
genes. Because 2R-ohnologues are enriched in signalling pro-
teins [6,7], this finding is consistent with cancer being a
disease in which regulatory processes go awry.
A second finding was that in a subset of cancers—particu-
larly melanoma, lung adenocarcinoma, breast and liver
cancers, B-cell lymphoma and medulloblastoma—there are
2R-ohnologue families in which one gene carries multiple
mutations in the cumulative data, while sister genes in the
same family are relatively mutation-free. Most notably, in 315
out of the 322 2R-ohnologue families displaying a high skew
in multiple cancers the same gene carries the heaviest ML in
each cancer, and for families of more than two members,
usually the second-ranked gene is also the same in each cancer.
Generally, each gene in a 2R-ohnologue family is on a
different chromosome, and the non-mutated 2R genes in
the ML-skewed families are widely distributed in the
genome. It therefore seems unlikely that all of these are in
genomic regions that are protected from mutation, though
this possibility must be formally tested.
Rather, we favour a conceptually simple working model
(figure 6). The invertebrate ancestor of the vertebrates is
depicted as having cells controlled by linear regulatory
pathways. Via the 2R-WGD leap, these pathways were quadru-
plicated, generating the complex networks that transmit
multiple regulatory signals in vertebrate cells. In certain cancers
such asmelanoma and breast cancer, heterogeneous patterns of
multiple mutations (black crosses in figure 6) result in the shut-
downof certain routes through these communication networks.
Information flow is therefore forced through a limited number
of ‘open’ network pathways, which are driven by activating
oncogenic driver mutations (star symbols in figure 6) and also
depend on specific non-mutated 2R-ohnologues as effectors.
In this model, driver mutations that activate the ‘open’
oncogenic pathways will be under positive selection, whereas
essential effectors of these drivers will be under purifying
selection to be maintained mutation-free. By contrast, 2R-
ohnologues in the ‘shut down’ part of the signalling network
will experience different selection pressures that vary with
time. Our findings indicate quantitative hierarchies in how
mutation burdens are distributed across 2R-ohnologue
families in cancers that conform to our model. We therefore
suggest that mutations that block tumour-suppressing path-
ways through the network will be under positive selection
until these routes are closed, at which time these pathways
will join the ones that are irrelevant to the cancer, where
further mutations will be under neutral selection.
The heterogeneity of so-called passenger mutations is
generally taken to imply that these represent clinically incon-
sequential ‘noise’. However, in our model such heterogeneity
reflects the possibility that there are multiple ways to disable
parts of the 2R-WGD networks, while still leaving the onco-
genic pathways open. These findings raise challenging
questions of redundancy and essentiality of family members
at the biochemical level. Why are certain 2R genes quantitat-
ively more important to a cancer than their sisters? As more
cancer mutation data are collected, it will be fascinating to see
how the overall ML rankings resolve.
Through this study, we realize that recurrent oncogenic
driver mutations, genes with multiple mutations and non-
mutated genes can each occur within the same 2R-ohnologue
family, or even in the same gene, in different cancer contexts.
8
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Figure 5. Relationships among ML of 2R-ohnologues in melanoma, cancer/
control mRNA expression in melanoma and proteins identified in 14-3-3-
affinity capture experiments using melanoma cell lysates. Each cross rep-
resents a gene in the E-GEOD-3189 transcription profiling dataset [34]. The
log2 ratio of mRNA expression in malignant melanoma versus benign mela-
nocytic lesions in the E-GEOD-3189 dataset is plotted on the y-axis against
the ML score of the gene calculated from the Alexandrov et al. [15] data
on the x-axis. The genes whose mRNA levels are most strongly up- or down-
regulated in melanoma are in red and blue, respectively. Also plotted (circles)
are the proteins that were isolated by 14-3-3-affinity capture of cell lysates
from both SKMEL13 and SBCL2 melanoma cells, and identified by mass spec-
trometric analyses. The data used for this figure are in the electronic
supplementary material, table S6.
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For example, neuroblastoma presented with only one ML-
skewed gene family (the ALK/LTK receptor tyrosine kinases),
which includes drivermutations known to activate ALK in this
disease [44]. However, the cumulative data for lung adenocar-
cinoma, breast and liver cancers contain a few hundred
different mutations in ALK, but few in its sister LTK, an imbal-
ance that is inconsistent with ALK being an activated driver in
these cancers.
An important question arising from our model is whether
the mutation-free 2R-ohnologues that are putative effectors
of oncogenic drivers will be good targets for therapeutic inter-
vention. While a logical proposition, unfortunately these
mutation-free genes are largely understudied. For example,
there is intense focus of research on the inactivating mutations
in APC in colorectal cancers [31]. However, it is conceivable
that the loss of APC renders these cancers dependent on
APC2, and to our knowledge this hypothesis has not been
tested. Similarly, many FOG2 mutations, but few in FOG1,
were found in 11 cancer types. Therefore, targeting FOG1 for
inactivation seems logical. Furthermore, the FOG family
(FOG2 most mutated) was among several 2R families whose
skewed MLs coincided with activating B-RafV600E and N-Ras
driver mutations in melanoma. Targeting aberrant Raf
signalling is therapeutic in melanoma [31,33], so it will be
important to define the biochemical relationships between
Ras–Raf signalling and FOG proteins in melanoma. Interest-
ingly, FOG1 interacts with the GATA transcription factors,
which include GATA2, which is essential for proliferation of
cancer cells carrying oncogenic K-Ras [45]. The type II PAK
kinases (PAK7 most mutated) also showed a ML skew in
melanomas with B-RafV600E and N-Ras driver mutations. Fur-
thermore, PAK4 and PAK6 have much lower MLs than PAK7
in six cancers; PAK4, PAK6 and PAK7 are 14-3-3-binding
phosphoproteins [42,46]; PAK4 was 14-3-3-affinity captured
here from melanoma cell lysates; and overexpressed PAK4
andPAK6weremore effective than PAK7 in enhancing the via-
bility of B-RafV600E-mutant melanoma cells exposed to
PLX4720 [43]. These findings suggest that, for unknown
reasons, the PAK4/PAK6 kinases are more important than
PAK7 in melanoma.
STRINGanalysis [47] revealed that the protein familieswith
ML skews in multiple cancers include regulatory proteins in
growth factor signalling (families whose most multiply-
mutated members are ERBB4, AKT3, GSK3B, ALK, KPCD1,
PAK7, KCC1D, AAKG2, KPCT, FER, PTPRD, LIPA2, PTPRR,
P2R3A, P85A, P3C2G, INP4B, PPM1H, IRS1, GRB2, RHEB,
OTU7A), chromatin function (FOG2, RUNX1, ANM8, TREF1,
SMYD3, HDAC9), membrane and cytoskeletal dynamics
Table 3. Overexpression of protein kinase 2R-ohnologues with low mutation scores decreased the sensitivity of B-RafV600E-mutant melanoma cells to PLX4720.
The viability score assigned by Wood et al. [43] refers to the ability of the protein kinase, when overexpressed, to enhance the viability of B-RafV600E-mutant
melanoma (A375) cells exposed to the B-RafV600E inhibitor, PLX4720. Seven 2R-ohnologue families of protein kinases had least one member among the top hits
of the Wood dataset [43] and at least one member with at least 10 mutations in melanoma in the Alexandrov dataset [15]. The cell viability scores [42] and
ML scores (this study) are shown for each member of these seven families. The family Id is an arbitrary number assigned to identify each 2R-ohnologue family
in [7]. n.a., data not available.
2R-ohnologue
family Id
protein
name
UniProt
Id
viability
score [42]
ML score in melanoma
(electronic supplementary
material, table S2)
is ML skew in melanoma above
threshold for inclusion in ﬁgure 3
and the electronic supplementary
material, table S3?
378 NTRK2 Q16620 1.23 0.0777 no
378 NTRK1 P04629 1.07 0.3932 no
378 NTRK3 Q16288 n.a. 0.2621 no
378 MUSK O15146 0.76 0.2670 no
1058 MST1R Q04912 1.13 0.2923 no
1058 MET P08581 1.03 0.7077 no
1085 MAPK8 P45983 1.18 0.1563 no
1085 MAPK9 P45984 0.93 0.3438 no
1085 MAPK10 P53779 0.79 0.5000 no
1548 SRPK3 Q9UPE1 1.16 0.2195 no
1548 SRPK1 Q96SB4 0.95 0.3415 no
1548 SRPK2 P78362 0.86 0.4390 no
1666 PIM2 Q9P1W9 1.15 0.3182 no
1666 PIM1 P11309 1.11 0.5000 no
1666 PIM3 Q86V86 n.a. 0.1818 no
1780 LIMK1 P53667 1.17 0.3103 no
1780 LIMK2 P53671 0.94 0.6897 no
2215 PAK6 Q9NQU5 1.21 0.0877 yes
2215 PAK4 O96013 0.97 0.0789 yes
2215 PAK7 Q9P286 0.86 0.8333 yes
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(UN13C, ELMO1, RAB3C, RB11A, TSNA1, RBG1L, MTUS2,
RASF9, GAS2, RHG06, RRAS2, EXT1, SYT1), neurotrans-
mission (AUTS2, DLG2, AMMR1, HIP1, CBLN2, NPAS3,
CABP8, BAI3, DAB1, SYNPR, DCC, 5HT2C, LIN7A, CRUM1,
ACM3, neurabin-1), ion channels (HCN1, KCIP4, KCAB1,
KCND2), protein glycosylation (XYLT1, MDGA2, MGT4C,
LARGE), extracellular matrix (TECTA, FREM2), angiogenesis
and responses to hypoxia (BAI3, EDIL3, EGLN3). While the
most mutated family members are listed here for linguistic
ease, we propose the least-mutated members for attention as
potential therapeutic targets. Many of these protein families
have known functional links with cancer and metastases, but
this dataset is also rich in ion channels and neurotransmitter
systems; this is intriguing, since most of the analysed cancers
are not in excitable nervous tissues. Interestingly, tumours exhi-
bit bioelectric changes and ion channel modulation is being
explored for cancer therapy [48,49].
A distinct subset of cancers (ALL, AML, bladder, colorec-
tal, glioblastoma, glioma, head-and-neck, ovary, kidney
chromophobe) was characterized by an ML skew towards
mutations in p53, and not p63 or p73. These cancers have
relatively few other 2R-ohnologue families with high ML
skews, and the ones that they did have generally differed
from the ML-skewed families in breast, melanoma, lung ade-
nocarcinoma and liver cancers. These ‘p53-mutated, but not
p63/p73-mutated’ cancers may therefore require a tailored
version of the model (figure 6) to be developed.
Finally, it has been considered paradoxical that ‘dangerous’
cancer genes from the 2R-WGD were selectively retained
during vertebrate evolution [11]. An alternative view is that
the robustness of 2R-ohnologue signal-multiplexing networks
enables vertebrates to survive long enough to develop
cancer. Mutating one 2R-ohnologue may not be lethal if
other members of the family can at least partially compensate.
However, if such mutations disconnect that protein family
from certain signalling networks, cells will get stuck in one sig-
nallingmode, generating the cancer phenotype. It is fascinating
to discover how an ancient evolutionary leap left its mark on
the genomes of vertebrate animals, on signalling complexity
and on the diseases of modern humans.
5. Material and methods
5.1. Mapping mutations to genes and computing
mutation load scores of 2R-ohnologues
The chromosomal locations of single and double nucleotide
substitutions, small insertions and deletions within the Alexan-
drov et al. [15] dataset were mapped onto nucleotide positions
hypothesis: in certain
cancers, heterogeneous
mutations   
disconnect parts of the
2R-WGD networks,
forcing information to
flow via restricted routes
that are activated by
specific driver
mutations      and
operated by non-
mutated effectors
simple
chordate
ancestor
signal
multiplexing
networks
vertebrate
phenotypic
variety
cancer
phenotype
2R-WGD
(b)(a) (c)
Figure 6. Simplified model that depicts cancer as a disorder of signal multiplexing in the cellular 2R-WGD networks of vertebrate animals. (a) The ancestor of all the
vertebrates was an invertebrate chordate whose cells are depicted as being under the control of simple linear regulatory pathways. The image is of amphioxus (Bran-
chiostoma), regarded as the best modern-day proxy for the ancestor. (b) 2R-WGD at the evolutionary origins of the vertebrate animals boosted communication networks
inside our cells. Variations in these networks may underpin variety of vertebrate cell types, species and behaviours. (c) We hypothesize that certain cancers arise when
different heterogeneous combinations of mutations (crosses) disconnect certain parts of the 2R-WGD regulatory networks and force too much communication flow via a
restricted number of oncogenic pathways. These ‘open’ oncogenic pathways are activated by specific driver mutations (stars) and also require effector proteins that must
remain mutation-free. If these effectors acquire too many deleterious mutations, the cancer cell will be lost. Though the model only depicts 2R families with high ML
skews, it could be extended to include other patterns. For example, 2R families whose members carry an even ML may be in parts of the network where any member can
perform the family function for the cancer, or represent functions whose total elimination gives a selective advantage to the cancer. In its simple form, the model assumes
that when genes are hit by a number of different mutations (crosses) these will include loss-of-function mutations. However, it is appreciated that this may not always be
so, in which case the rules of the model would change. The model highlights that the contribution of both mutated and non-mutated 2R-ohnologues to the overall
function of each family in the cancer should be considered.
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within protein-coding and pseudogene-RNA genes in the
Ensembl 72 dataset. Briefly, the BioMart service of Ensembl
(www.ensembl.org) was used to retrieve the gene positions,
and a Python script was compiled to identify the mutations
that map within a given gene. Mutations involving more than
one nucleotide were mapped to the first nucleotide change.
Each mutation that maps onto the same starting nucleotide
was considered only once. For example, for the B-Raf gene,
the V600L and V600K amino acid substitutions start on the
same nucleotide (1798G. C and 1798_1799GT.AA, respect-
ively) and would count as one, whereas the V600E substitution
starts one base after (1799T.A) and would be counted separ-
ately. Gene copy number changes and changes involving more
thanone genewere not considered.Genes annotated as pseudo-
genes were included in our analysis, because functions have
been identified for many such genes.
The ML for each gene was computed by summing the
total number of different mutations identified for a gene
(PROT ML) divided by the sum of all mutations identified
in the 2R-ohnologue family components of the gene under
analysis. This number scores from 1 to 0 and identifies the
genes in any 2R-ohnologue family that are prone to accumu-
late mutations (score close to 1) or are clear of mutations
(score close to 0).
The genomic nucleotide positions of mutations were trans-
latedwith a Python script into the transcript nucleotide position
of a protein-coding gene for making pictures of the MLs of the
different family members. The BioMart service of Ensembl was
used to retrieve the transcript genomic coordinates, and the
longest transcript for each gene was used for this analysis.
5.2. Lack of mutations: biological reality or
missing data?
The mutation data were derived from 507 whole genome and
6535 exome sequencing studies, and further sequencing vali-
dation experiments performed by Alexandrov et al. [15], the
Cancer Genome Atlas, International Cancer Genome Consor-
tium and other laboratories [15]. For our study, it was critical
that genes that record few mutations represent biological reality
and not false negatives due to lack of sequence coverage. There
isunevenness in thedatasetbecause,while theexomeenrichment
platforms thatwere used (Agilent,Nimblegen and Illumina) cap-
ture mainly protein-coding regions of genes, the Illumina
platform gives reads in 30 and 50 untranslated regions (UTRs)
[50] (figure 2b; electronic supplementary material, data file S2).
However, we did not exclude UTRs from our analysis, after
checking that this would not have a general effect on which
2R-ohnologue families were designated to display an ML skew.
Each exomesequencingplatformmisses certain ‘difficult’ regions
[50]. However, with the possible exception of pseudogenes, the
raw data in the primary studies cited in [15] give no indication
of technical biases that would result in specific genes being
systematically missed in the cumulative data.
5.3. Melanoma cell culture, 14-3-3-affinity
chromatography and mass spectrometric
identification of proteins
SKMEL13 (B-RAFV600E) and Sbcl2 (N-RASQ61K) melanoma
cells were cultured in RPMI and Dulbecco’s modified
eagle medium, respectively. Media were supplemented
with 10% (v/v) fetal calf serum (Thermo Scientific), 2 mM
L-glutamine, 50 units ml21 penicillin G and 50 mg ml21
streptomycin (Life Technologies), and cells cultured under
5% CO2 at 378C. Lysates were prepared as in [51] and subject
to 14-3-3-affinity chromatography. Briefly, proteins were
bound to 14-3-3-Sepharose, and specifically bound proteins
eluted by competition with the 14-3-3-binding synthetic
phosphopeptide, ARAApSAPA, as in [35] except that the
high salt wash was only 500 ml and the mock peptide elution
was omitted. The eluted proteins were denatured in 4 LDS
sample buffer (Life Technologies) containing 10% sample
reducing agent at 708C for 10 min, cooled and alkylated
with 50 mM iodoacetamide for 30 min in the dark at
room temperature. Proteins were separated on NuPAGE
4–12% gradient gels and stained with colloidal Coomassie
Blue (Life Technologies). Gel lanes were cut into 20 sections
(electronic supplementary material, figure S6), which
were washed successively with 50 mM triethylammonium
bicarbonate; 50% acetonitrile, 50 mM triethylammonium
bicarbonate (twice); and acetonitrile (15 min each wash),
before drying in a SpeedVac (Eppendorf). Trypsin
(5 mg ml21 trypsin gold; Promega) in sufficient 25 mM
triethylammonium bicarbonate to cover the gel pieces was
added for 12 h at 308C. Supernatant was transferred to a
fresh tube, to which two 50% acetonitrile washes of the gel
pieces were also added. The digested samples were dried,
and each digest was redissolved in 2 ml of 25 mM sodium
acetate buffer, pH 5.5, 30 mM sodium cyanoborohydride
containing 0.2% (v/v) formaldehyde and incubated at
room temperature for 15 min. Tryptic digests were analysed
using Ultimate 3200 nanoflow chromatography (LC Packings)
coupled to an LTQ-Orbitrap (Thermo Finnigan) mass spec-
trometer equipped with a dynamic NanoSpray source
(Optron). For protein identification, mass spectrawere acquired
using the LTQ-Orbitrap programmed to perform two FT
scans (60 000 resolution) on 300–800 and 800–1800 amu mass
ranges with the top five ions from each scan selected for
LTQ-MS/MS. FT spectra were internally calibrated using a
single lock mass (445.1200 atomic mass units). Raw files
were converted to peak lists in Mascot generic format
(MGF) files using RAW2MSM v. 1.7 software (Matthias Mann)
using default parameters and without any filtering, charge
state deconvolution or deisotoping. MGF files were searched
using a Mascot 2.2 in-house server against the Internatio-
nal Protein Index human 3.26 database (57 846 sequences;
26 015 783 residues).
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